113 related articles for article (PubMed ID: 28744813)
1. Inhibition of protein kinase CK2 sensitizes non-small cell lung cancer cells to cisplatin via upregulation of PML.
Yang B; Yao J; Li B; Shao G; Cui Y
Mol Cell Biochem; 2017 Dec; 436(1-2):87-97. PubMed ID: 28744813
[TBL] [Abstract][Full Text] [Related]
2. A CK2-dependent mechanism for degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Cai LF; Erdjument-Bromage H; Kaufman AJ; Singh B; Teruya-Feldstein J; Tempst P; Pandolfi PP
Cell; 2006 Jul; 126(2):269-83. PubMed ID: 16873060
[TBL] [Abstract][Full Text] [Related]
3. EHD1 confers resistance to cisplatin in non-small cell lung cancer by regulating intracellular cisplatin concentrations.
Gao J; Meng Q; Zhao Y; Chen X; Cai L
BMC Cancer; 2016 Jul; 16():470. PubMed ID: 27411790
[TBL] [Abstract][Full Text] [Related]
4. miR-181a and miR-630 regulate cisplatin-induced cancer cell death.
Galluzzi L; Morselli E; Vitale I; Kepp O; Senovilla L; Criollo A; Servant N; Paccard C; Hupé P; Robert T; Ripoche H; Lazar V; Harel-Bellan A; Dessen P; Barillot E; Kroemer G
Cancer Res; 2010 Mar; 70(5):1793-803. PubMed ID: 20145152
[TBL] [Abstract][Full Text] [Related]
5. CK2 and PML: regulating the regulator.
Lallemand-Breitenbach V; de Thé H
Cell; 2006 Jul; 126(2):244-5. PubMed ID: 16873055
[TBL] [Abstract][Full Text] [Related]
6. TAB3 overexpression promotes cell proliferation in non-small cell lung cancer and mediates chemoresistance to CDDP in A549 cells via the NF-κB pathway.
Chen J; Gu J; Feng J; Liu Y; Xue Q; Ni T; Wang Z; Jia L; Mao G; Ji L
Tumour Biol; 2016 Mar; 37(3):3851-61. PubMed ID: 26476534
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of CK2 enhances UV-triggered apoptotic cell death in lung cancer cell lines.
Zhao T; Jia H; Li L; Zhang G; Zhao M; Cheng Q; Zheng J; Li D
Oncol Rep; 2013 Jul; 30(1):377-84. PubMed ID: 23595577
[TBL] [Abstract][Full Text] [Related]
8. Novel CK2-Specific Pt(II) Compound Reverses Cisplatin-Induced Resistance by Inhibiting Cancer Cell Stemness and Suppressing DNA Damage Repair in Non-small Cell Lung Cancer Treatments.
Wang Y; Wang X; Xu G; Gou S
J Med Chem; 2021 Apr; 64(7):4163-4178. PubMed ID: 33784109
[TBL] [Abstract][Full Text] [Related]
9. Association of protein kinase CK2 inhibition with cellular radiosensitivity of non-small cell lung cancer.
Li Q; Li K; Yang T; Zhang S; Zhou Y; Li Z; Xiong J; Zhou F; Zhou X; Liu L; Meng R; Wu G
Sci Rep; 2017 Nov; 7(1):16134. PubMed ID: 29170453
[TBL] [Abstract][Full Text] [Related]
10. CK2 mediates phosphorylation and ubiquitin-mediated degradation of the PML tumor suppressor.
Scaglioni PP; Yung TM; Choi S; Baldini C; Konstantinidou G; Pandolfi PP
Mol Cell Biochem; 2008 Sep; 316(1-2):149-54. PubMed ID: 18566754
[TBL] [Abstract][Full Text] [Related]
11. Phosphorylation of IGFBP-3 by Casein Kinase 2 Blocks Its Interaction with Hyaluronan, Enabling HA-CD44 Signaling Leading to Increased NSCLC Cell Survival and Cisplatin Resistance.
Coleman KL; Chiaramonti M; Haddad B; Ranzenberger R; Henning H; Al Khashali H; Ray R; Darweesh B; Guthrie J; Heyl D; Evans HG
Cells; 2023 Jan; 12(3):. PubMed ID: 36766747
[TBL] [Abstract][Full Text] [Related]
12. IGFBP-3 methylation-derived deficiency mediates the resistance to cisplatin through the activation of the IGFIR/Akt pathway in non-small cell lung cancer.
Cortés-Sempere M; de Miguel MP; Pernía O; Rodriguez C; de Castro Carpeño J; Nistal M; Conde E; López-Ríos F; Belda-Iniesta C; Perona R; Ibanez de Caceres I
Oncogene; 2013 Mar; 32(10):1274-83. PubMed ID: 22543588
[TBL] [Abstract][Full Text] [Related]
13. AKT/mTOR down-regulation by CX-4945, a CK2 inhibitor, promotes apoptosis in chemorefractory non-small cell lung cancer cells.
So KS; Rho JK; Choi YJ; Kim SY; Choi CM; Chun YJ; Lee JC
Anticancer Res; 2015 Mar; 35(3):1537-42. PubMed ID: 25750308
[TBL] [Abstract][Full Text] [Related]
14. Curcumin downregulates p38 MAPK-dependent X-ray repair cross-complement group 1 (XRCC1) expression to enhance cisplatin-induced cytotoxicity in human lung cancer cells.
Tung CL; Jian YJ; Chen JC; Wang TJ; Chen WC; Zheng HY; Chang PY; Liao KS; Lin YW
Naunyn Schmiedebergs Arch Pharmacol; 2016 Jun; 389(6):657-66. PubMed ID: 27026405
[TBL] [Abstract][Full Text] [Related]
15. Cyclic GMP/protein kinase G type-Iα (PKG-Iα) signaling pathway promotes CREB phosphorylation and maintains higher c-IAP1, livin, survivin, and Mcl-1 expression and the inhibition of PKG-Iα kinase activity synergizes with cisplatin in non-small cell lung cancer cells.
Wong JC; Bathina M; Fiscus RR
J Cell Biochem; 2012 Nov; 113(11):3587-98. PubMed ID: 22740515
[TBL] [Abstract][Full Text] [Related]
16. NEAT1 upregulates EGCG-induced CTR1 to enhance cisplatin sensitivity in lung cancer cells.
Jiang P; Wu X; Wang X; Huang W; Feng Q
Oncotarget; 2016 Jul; 7(28):43337-43351. PubMed ID: 27270317
[TBL] [Abstract][Full Text] [Related]
17. IGFBP-3 hypermethylation-derived deficiency mediates cisplatin resistance in non-small-cell lung cancer.
Ibanez de Caceres I; Cortes-Sempere M; Moratilla C; Machado-Pinilla R; Rodriguez-Fanjul V; Manguán-García C; Cejas P; López-Ríos F; Paz-Ares L; de CastroCarpeño J; Nistal M; Belda-Iniesta C; Perona R
Oncogene; 2010 Mar; 29(11):1681-90. PubMed ID: 20023704
[TBL] [Abstract][Full Text] [Related]
18. ATF2 contributes to cisplatin resistance in non-small cell lung cancer and celastrol induces cisplatin resensitization through inhibition of JNK/ATF2 pathway.
Lo Iacono M; Monica V; Vavalà T; Gisabella M; Saviozzi S; Bracco E; Novello S; Papotti M; Scagliotti GV
Int J Cancer; 2015 Jun; 136(11):2598-609. PubMed ID: 25359574
[TBL] [Abstract][Full Text] [Related]
19. Cisplatin-enriching cancer stem cells confer multidrug resistance in non-small cell lung cancer via enhancing TRIB1/HDAC activity.
Wang L; Liu X; Ren Y; Zhang J; Chen J; Zhou W; Guo W; Wang X; Chen H; Li M; Yuan X; Zhang X; Yang J; Wu C
Cell Death Dis; 2017 Apr; 8(4):e2746. PubMed ID: 28406482
[TBL] [Abstract][Full Text] [Related]
20. Suppression of EIF4G2 by miR-379 potentiates the cisplatin chemosensitivity in nonsmall cell lung cancer cells.
Hao GJ; Hao HJ; Ding YH; Wen H; Li XF; Wang QR; Zhang BB
FEBS Lett; 2017 Feb; 591(4):636-645. PubMed ID: 28117895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
